Business Context and Reporting Period
Company: Denali Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2026
Reporting Period: Single event date (May 21, 2026)
This filing serves as a Regulation FD disclosure regarding the announcement of topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson's disease. The announcement was made jointly with Biogen Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-driven report focused on clinical trial results rather than a periodic financial statement.
Material Changes
Clinical Development Update:
- Announcement of topline results for the Phase 2b LUMA study.
- Study evaluates BIIB122 (DNL151) for early-stage Parkinson's disease.
- Collaboration partner: Biogen Inc.
Financial Impact: The filing does not quantify any immediate financial changes, revenue recognition, or expense adjustments resulting from this announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) containing the specific details of the study results. The text of the 8-K itself does not contain forward-looking guidance, updated financial outlooks, or specific risk factors beyond the standard disclosure that the information is not deemed "filed" under Section 18 of the Exchange Act.
Unusual Items: None reported in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety data from the LUMA study.
- Verify the statistical significance of the topline results announced.
- Assess the potential impact of these results on the commercial partnership with Biogen Inc.
- Monitor subsequent filings for any updates to the company's financial guidance or development timeline based on these results.